Funding to develop targeted kinase inhibitors for treatment of hematopoietic cancers
Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing.
The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.
“We are excited to have the support of exceptional investors. This financing allows us to expand our R&D program to substantially de-risk compound selection as we identify our first development candidate in advance of IND filing,” said Kurome Chief Executive Officer and Chief Scientific Officer Jan Rosenbaum, PhD.
“We are excited to be aligned with the leading experts in the IRAK1/4 signaling pathway and are impressed with the level of development and data generated by Kurome to date,” said Daniel Heller, General Partner and Chief Investment Officer at Affinity Asset Advisors.
Launched in 2020, Kurome secured initial seed funding led by CincyTech based on research at Cincinnati Children’s Hospital Medical Center in collaboration with the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS).
“In multi-factorial hematological malignancies like AML, we are excited by the early clinical data of combined IRAK4 and FLT3 inhibition in patients. The Kurome team has generated compelling preclinical data that suggests a differentiated approach with potential advantages over others in this emerging space,” said Aaron Kantoff, Venture Partner at Medicxi.
Aaron Kantoff, Venture Partner at Medicxi and Daniel Heller, General Partner and Chief Investment Officer at Affinity Asset Advisors will join the Kurome Therapeutics Board of Directors.
###
Media Contact
Byron McCauley
[email protected]
